Zeneca "superstatin"
Executive Summary
First regulatory submission for ZD4522, an HMG-CoA reductase inhibitor with a "superstatin" profile, is expected in three years, Zeneca says. ZD4522 "has the potential at well tolerated doses of lowering" LDL-cholesterol and triglycerides "to a much greater extent than the first generation of statins," according to the company. Zeneca licensed ZD4522 (formerly S-4522) from Japan-based Shionogi and has taken on worldwide development, commercialization and marketing for the agent...